Reclassification of good-risk seminoma: prognostic factors, novel biomarkers and implications for clinical management. (18th March 2019)

• Record Type: Journal Article
• Authors: Casadei, Chiara; Schepisi, Giuseppe; Menna, Cecilia; Chovanec, Michal; Gurioli, Giorgia; Gallà, Valentina; Altavilla, Amelia; Marcellini, Massimo; Bellia, Salvatore Roberto; Lolli, Cristian; Mego, Michal; Rosti, Giovanni; De Giorgi, Ugo
• Is Part Of: Future oncology. Volume 15:Number 12(2019)
• Page Start: 1347
• Page End: 1352
• Publication Date: 2019-03-18
• Subjects: α-fetoprotein -- biomarkers -- bleomycin -- chemotherapy -- germ cell tumors -- high-dose -- human chorionic gonadotropin -- metastases -- platinum -- prognosis -- seminoma; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2018-0850
• Languages: English
• ISSNs: 1479-6694

Abstract

Germ cell tumors represent 11% of the cancers diagnosed in adolescent males and are the most common solid tumors in adult men between the ages of 20 and 35. Pure seminoma accounts for around 50% of all testicular germ cell tumors. The prognostic classification of the International Germ Cell Cancer Collaborative Group for good-prognosis seminoma includes both nodal disease and pulmonary visceral metastases. In this article, we analyzed recent data on prognosis and outcome of good-prognosis seminoma to revise the traditional classification of the disease and improve tailored treatment.